Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Innovent and Daiichi Sankyo sign deal for Vanflyta in China | PharmaVoice

Pharma Tech

Innovent and Daiichi Sankyo sign deal for Vanflyta in China

Aug 10, 2026, 9:44 AM

Read Full Article → Innovent and Daiichi Sankyo sign deal for Vanflyta in China

Innovent and Daiichi Sankyo sign deal for Vanflyta in China

Translate article text

Choose a language and wait for the translated text.

Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement to commercialise Vanflyta, an oral type II FLT3 inhibitor, in China.